Cardiovascular risk and atherosclerosis prevention

被引:67
|
作者
Frohlich, Jiri [1 ]
Al-Sarraf, Ahmad [1 ]
机构
[1] St Pauls Hosp, Healthy Heart Program, Prevent Clin, Vancouver, BC V6Z 1Y6, Canada
关键词
Coronary artery disease; Framingham Heart Study; Risk scores; Lipoprotein (a); C-reactive protein; Myeloperoxidase; Lifestyle; Medications; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; UNITED-KINGDOM; FOLLOW-UP; FRAMINGHAM; MEN; SCORE;
D O I
10.1016/j.carpath.2012.03.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Until recently, coronary artery disease (CAD) was the leading cause of death in the developed countries. Its remarkable decline can be attributed to our knowledge of the major risk factors identified by several studies resulting in better prevention and treatment. Of the major risk factors, the ratio of apolipoprotein (apo) B/apo A1 followed by smoking, diabetes, and hypertension are the most important. A number of risk scores for men and women are now available to estimate the likelihood of development of CAD. However, because of the risk of CAD differs in various populations, some of the algorithms are more appropriate for some countries but not suitable for others. These risk assessment algorithms differ in the parameters they use. All the risk scores have some limitations such as different study populations; the age of the study is also different, and number of points awarded for age categories also differs among the various algorithms. In an effort to further improve the risk prediction, a number of biomarkers have been studied. In addition to plasma lipids, a lot of interest has focused on apo measurements; particularly of apo B. Another valuable biomarker is lipoprotein (a) [Lp(a)]. Lp(a) is not only atherogenic as low-density lipoprotein (LDL) but also prothrombotic, and several studies indicate that Lp(a) is an independent risk factor for CAD. The lipid profile provides a framework for appropriate management. This includes therapeutic lifestyle changes and medications. Lifestyle interventions are the cornerstone of CAD prevention strategies and are the first step in risk factor management. Of particular importance are smoking cessation, achievement and maintenance of ideal body weight, regular exercise, reduction in the intake of saturated fat and sugars, and decreasing level of stress. Of medications, lipid-lowering, anti-hypertensive, and anti-coagulant can be effectively used. The current strategies for risk assessment and prevention have been very successful contributing to the more than 50% decrease in CAD mortality over the last 20 years. Thus, in Canada, cardiovascular disease is no longer the leading cause of death. Crown Copyright (c) 2013 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:16 / 18
页数:3
相关论文
共 50 条
  • [1] Atherosclerosis imaging for risk assessment and primary prevention of cardiovascular disease
    Grundy, SM
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2003, 46 (02) : 115 - 121
  • [2] Pharmacological prevention of atherosclerosis and cardiovascular disease
    Paoletti, R
    [J]. ATHEROSCLEROSIS, 1998, 136 : S25 - S25
  • [3] Relationship between cardiovascular global risk in primary and secondary prevention and carotid atherosclerosis
    Castelnuovo, S.
    Frigerio, B.
    De Giosa, G.
    Amato, M.
    Tremoli, E.
    Sirtori, C. R.
    Baldassarre, D.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 259 - 259
  • [4] Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the Cardiovascular Health Index in the primary prevention population?
    Singh, Sarah S.
    Pilkerton, Courtney S.
    Shrader, Carl D., Jr.
    Frisbee, Stephanie J.
    [J]. BMC PUBLIC HEALTH, 2018, 18
  • [5] Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the Cardiovascular Health Index in the primary prevention population?
    Sarah S. Singh
    Courtney S. Pilkerton
    Carl D. Shrader
    Stephanie J. Frisbee
    [J]. BMC Public Health, 18
  • [6] Atherosclerosis in the young: Risk and prevention
    Strong, JP
    [J]. HOSPITAL PRACTICE, 1999, 34 (10): : 15 - +
  • [7] Effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention
    Bard, RL
    Kalsi, H
    Rubenfire, M
    Wakefield, T
    Fex, B
    Rajagopalan, S
    Brook, RD
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (08): : 1030 - 1032
  • [8] The effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention
    Bard, RL
    Brook, RD
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 149A - 149A
  • [9] Influenza and atherosclerosis: vaccination for cardiovascular disease prevention
    Madjid, M
    Awan, I
    Ali, M
    Frazier, L
    Casscells, W
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (01) : 91 - 96
  • [10] Surrogate markers, atherosclerosis and cardiovascular disease prevention
    Wierzbicki, A. S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (07) : 981 - 987